Literature DB >> 24770939

[Non- inferior moderate hypofractionated irradiation of glottis T1/T2 laryngeal cancer ].

Martina Becker-Schiebe1, Hans Christiansen.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24770939     DOI： 10.1007/s00066-014-0663-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  11 in total

1.  Repopulation during radical radiotherapy for T1 glottic cancer.

Authors:  K Saarilahti; M Kajanti; H Lehtonen; T Hämäläinen; H Joensuu
Journal:  Radiother Oncol       Date:  1998-05       Impact factor: 6.280

2.  High daily fraction dose external radiotherapy for T1 glottic carcinoma: treatment results and prognostic factors.

Authors:  Melis Gultekin; Enis Ozyar; Mustafa Cengiz; Gokhan Ozyigit; Mutlu Hayran; Sefik Hosal; Fadil Akyol
Journal:  Head Neck       Date:  2011-11-02       Impact factor: 3.147

3.  Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0 disease.

Authors:  Enrico Cellai; Paolo Frata; Stefano M Magrini; Fabiola Paiar; Raffaella Barca; Simona Fondelli; Caterina Polli; Lorenzo Livi; Bartolomea Bonetti; Elisabetta Vitali; Agostina De Stefani; Michela Buglione; Gianpaolo Biti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-08-10       Impact factor: 7.038

4.  Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time.

Authors:  Hideya Yamazaki; Kinji Nishiyama; Eiichi Tanaka; Masahiko Koizumi; Masashi Chatani
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-19       Impact factor: 7.038

5.  Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control.

Authors:  Y Nishimura; Y Nagata; K Okajima; M Mitsumori; M Hiraoka; S Masunaga; K Ono; K Shoji; H Kojima
Journal:  Radiother Oncol       Date:  1996-09       Impact factor: 6.280

6.  Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.

Authors:  Jens Overgaard; Hanne Sand Hansen; Lena Specht; Marie Overgaard; Cai Grau; Elo Andersen; Jens Bentzen; Lars Bastholt; Olfred Hansen; Jørgen Johansen; Lisbeth Andersen; Jan F Evensen
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

Review 7.  Management of T1-T2 glottic carcinomas.

Authors:  William M Mendenhall; John W Werning; Russell W Hinerman; Robert J Amdur; Douglas B Villaret
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

8.  The impact of treatment time and smoking on local control and complications in T1 glottic cancer.

Authors:  J C van der Voet; R B Keus; A A Hart; F J Hilgers; H Bartelink
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-09-01       Impact factor: 7.038

9.  T1-T2 squamous cell carcinoma of the glottic larynx treated with radiation therapy: relationship of dose-fractionation factors to local control and complications.

Authors:  W M Mendenhall; J T Parsons; R R Million; G H Fletcher
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-12       Impact factor: 7.038

10.  Radiotherapy with fraction size of 2.25 Gy in T1-2 laryngeal and hypopharyngeal cancer.

Authors:  Kumiko Karasawa; Hiroaki Kunogi; Takahisa Hirai; Hidehiro Hoji; Hisako Hirowatari; Hiromi Izawa; Kana Ito; Keisuke Sasai; Tomohisa Furuya; Shuichi Ozawa; Fumihiko Matsumoto; Shin Ito; Shinichi Oba
Journal:  J Radiat Res       Date:  2013-01-07       Impact factor: 2.724
View more
  2 in total

1.  T1-2 glottic cancer treated with radiotherapy and/or surgery.

Authors:  Mohamed Shelan; Lukas Anschuetz; Adrian D Schubert; Beat Bojaxhiu; Alan Dal Pra; Frank Behrensmeier; Daniel M Aebersold; Roland Giger; Olgun Elicin
Journal:  Strahlenther Onkol       Date:  2017-05-04       Impact factor: 3.621

2.  Influencing Factors on Radiotherapy Outcome in Stage I-II Glottic Larynx Cancer-A Multicenter Study.

Authors:  Olgun Elicin; Ekin Ermiş; Christoph Oehler; Daniel M Aebersold; Francesca Caparrotti; Frank Zimmermann; Gabriela Studer; Guido Henke; Lukas Adam; Lukas Anschuetz; Mahmut Ozsahin; Matthias Guckenberger; Mohamed Shelan; Nuri Kaydıhan; Oliver Riesterer; Robin J D Prestwich; Thierry Spielmann; Roland Giger; Mehmet Şen
Journal:  Front Oncol       Date:  2019-09-20       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.